ABUS vs EPAM · P/E 5.4, rev $6.2M vs P/E 14, rev $4.73B
Arbutus Biopharma Corp (ABUS) versus EPAM Systems Inc (EPAM) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
EPAM Systems Inc (EPAM) is a information technology services company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported EPAM revenue for 2024-12-31 was $4.73B. Net income was $454.5M. Revenue was up 0.8% from 2023-12-31 to 2024-12-31. EPAM currently screens at market cap $5.10B and trailing P/E 14.0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. EPAM currently screens at market cap $5.10B and trailing P/E 14.0.
Not investment advice. Open the ABUS and EPAM stock pages for the full models.
Not investment advice.